Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET: Vortioxetine Relapse Prevention in MDD
NCT02371980Phase 4Completed
- Sponsor
- Takeda
- Start
- Feb 2015
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Takeda. Primary endpoint: Time From Randomization to Relapse of Major Depressive Disorder During the First 28 Weeks of the 32-Week Double-Blind Treatment Period. Started Feb 2015; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02371980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371980.